NCT00721799 · ADVERSE EVENTS

Adverse events

F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients · Source last updated 2019-08-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 1 calendar day following injection with the tracer agent, FLT
Other-event reporting threshold: 2%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
FLT PET Subjects who receive F-18 Fluorothymidine \[FLT\]PET imaging prior to treatment. F-18 Fluorothymidine: FLT PET scan \[0.04 to 0.08 mCi/kg (maximum of 5 mCi +/- 10%)\]	0 / 26	0 / 26	6 / 26

Group identifiers: EG000: FLT PET

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

deaths Num Affected
6
deaths Num At Risk
26
description
Subjects who receive F-18 Fluorothymidine \[FLT\]PET imaging prior to treatment. F-18 Fluorothymidine: FLT PET scan \[0.04 to 0.08 mCi/kg (maximum of 5 mCi +/- 10%)\]
id
EG000
other Num Affected
0
other Num At Risk
26
serious Num Affected
0
serious Num At Risk
26
title
FLT PET

frequency Threshold

time Frame

1 calendar day following injection with the tracer agent, FLT

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice